Sir, The global spread of New Delhi metallo-b-lactamase (NDM)-producing Enterobacteriaceae is of significant public health concern.
1 To date, NDM-producing Enterobacteriaceae have been isolated from numerous geographical regions, including Europe, North America, Australia and New Zealand. 1 In addition to hydrolysing carbapenems, NDM-producing organisms display resistance to a broad range of antimicrobial classes, primarily due to the presence of additional acquired plasmid-associated resistance genes. 2 As a result, infections caused by these organisms pose a considerable therapeutic challenge.
Transrectal ultrasound (TRUS)-guided prostate biopsy is a commonly performed urological outpatient procedure, with 1 000000 biopsies performed annually in the USA. 3 A variety of infectious complications have been reported following TRUS biopsy, ranging from urinary tract infection through to bacteraemia and sepsis.
3,4 Of note, the incidence of infectious complications following TRUS biopsy is reportedly increasing, with clinical and economic consequences.
3,5 The most common pathogen in the setting of post-biopsy sepsis is Escherichia coli, with causative strains probably originating from the patient's own endogenous flora. Over the past decade, the prevention and management of TRUS-biopsy infections due to E. coli has become more complicated due to increasing antimicrobial resistance in this organism. Currently, the most common resistance profiles encountered in this setting are fluoroquinolone resistance and/or extendedspectrum b-lactamase (ESBL) production. 3, 6 Recent studies suggest that pre-biopsy screening for such resistant pathogens with subsequent 'tailored' prophylaxis based on antimicrobial susceptibility results may be an effective way to reduce infectious complications.
3,7 To date, however, there are no reports describing pre-TRUS biopsy isolation of carbapenemase-producing E. coli. Here, we describe the isolation of NDM-1-producing E. coli from a patient undergoing rectal screening prior to TRUS biopsy.
In early 2013, an elderly New Zealand male attended the urology outpatient clinic for a pre-biopsy rectal screen. A TRUS biopsy 15 months earlier had demonstrated the presence of lowgrade prostatic carcinoma, and the patient was being monitored by regular measurement of prostate-specific antigen (PSA) levels and outpatient clinic assessments. In order to assess possible progression of his carcinoma, a repeat biopsy was recommended. In the month before attending for pre-biopsy rectal screening, the patient had returned from visiting relatives in India. He had no known healthcare contact during this trip.
Rectal screening for pre-TRUS biopsy carriage of fluoroquinolone-resistant E. coli was introduced in Auckland City Hospital, New Zealand in March 2012. Where possible, rectal swabs obtained from patients pre-TRUS biopsy are incubated aerobically overnight in MacConkey broth containing 1 mg/L ciprofloxacin. Isolates growing in this broth are then subcultured onto MacConkey agar containing 1 mg/L ciprofloxacin. Any E. coli isolates growing after 24 h are identified using the Bruker MALDI-TOF system, and antimicrobial susceptibility testing is performed using agar dilution according to CLSI guidelines. 8 The patient's pre-biopsy rectal swab grew a fluoroquinoloneresistant E. coli that was also resistant to penicillins, extendedspectrum cephalosporins, carbapenems, piperacillin/tazobactam, aztreonam, aminoglycosides and trimethoprim/sulfamethoxazole. The isolate tested susceptible to fosfomycin and nitrofurantoin. Double-disc synergy testing using meropenem or ertapenem with either EDTA or dipicolinic acid as inhibitors was positive, but the modified Hodge test was negative. PCR analysis and DNA sequencing demonstrated the presence of the bla NDM-1 and bla CTX-M-15 genes. In addition, the isolate was also found to harbour the aac-6 ′ -Ib and rmtC genes. Multilocus sequence typing (MLST) analysis was performed as previously described (http://mlst.ucc.ie/ mlst/dbs/Ecoli), and revealed sequence type (ST) 101.
Given the risk of a post-biopsy infection with extremely limited treatment options, along with the patient's advanced age and the low-grade nature of his carcinoma, a decision was made not to proceed with biopsy.
This case illustrates the increasingly complex challenges caused by antimicrobial resistance in the context of TRUS biopsy. Although for many patients colonized with fluoroquinolone-resistant E. coli, pre-biopsy screening and 'targeted' prophylaxis may be a useful preventative strategy, 7,9 for patients colonized with extremely resistant organisms such as NDM-producing E. coli, options for targeted prophylaxis and potential treatment may be so limited that the benefit of proceeding with biopsy may itself need to be called into question. Although fosfomycin has shown initial efficacy in preventing post-TRUS biopsy infections with antimicrobial-resistant pathogens, susceptibility of NDM-producing Enterobacteriaceae to fosfomycin remains variable. 10 Given the global dissemination of bla NDM -producing Enterobacteriaceae, coupled with the large number of TRUS biopsies performed in many regions, it seems inevitable that these organisms will continue to be isolated in the setting of TRUS biopsy-related sepsis. Accordingly, a pragmatic approach to undertaking TRUS biopsy seems indicated, including not only a tailoring of prophylaxis based on the patient's colonization status, but also a careful reassessment of the overall net benefit and clinical utility of the procedure itself, particularly in patients found to be colonized with highly resistant pathogens such as NDM-producing E. coli.
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None to declare. Sir, We read with interest this journal's recent Leading article concerning the national burden of infections after transrectal ultrasonographyguided prostate biopsy (TRUSgpb) 1 and the need for urgent action to reduce infectious complications. The authors discuss a number of possible strategies, including alterations in antimicrobial prophylaxis. We recently performed an audit cycle to specifically assess one such strategy.
In 2009, we published our Trust's post-TRUSgpb infection data for the year October 2007-September 2008. 2 Although the incidence of urosepsis [7/256 (2.7%) biopsies, including 4 (1.6%) bacteraemias] was not out of keeping with other reports, our prime concern was the multiresistant nature of the pathogens, with 100% ciprofloxacin resistance and 57% extended-spectrum b-lactamase (ESBL) production. During this time, the antibiotic prophylaxis regimen comprised ciprofloxacin and metronidazole for 1 day prior to biopsy and 2 days post-biopsy. To lessen effects on the bowel flora before the procedure, and to align with protocols used in other centres, prophylaxis was altered to begin just 2 h before biopsy (a reduction of two doses of ciprofloxacin and three of metronidazole). Our infection rate was then reaudited over 2 years.
Some 547 TRUSgpbs were performed between 1 July 2009 and 30 June 2011 at Wycombe Hospital. All patients were prescribed 500 mg of ciprofloxacin every 12 h plus 400 mg of metronidazole every 8 h, starting 2 h prior to the procedure and continuing until 48 h post-procedure. Subsequent cases of urosepsis (bacteraemia plus those with positive urine cultures requiring readmission) were identified and their notes reviewed. Table 1 combines the results from both audits. In the second study period, urosepsis was diagnosed following 4 of 547 procedures (0.73%), with three confirmed bacteraemic episodes. In comparison with the initial audit, the bacteraemia rate was not significantly reduced (3/547 versus 4/256, P¼ 0.218, Fisher's exact test), but the decrease in the overall urosepsis rate reached statistical significance (4/547 versus 7/256, P ¼ 0.044). In the 2009-11 period, all four cases were caused by Escherichia coli, with all strains being ciprofloxacin resistant. Only one was an ESBL producer, but two were also gentamicin resistant.
As described by Batura and Gopal Rao, 1 the increased incidence of urosepsis post-TRUSgpb in recent years has fuelled interest in how to improve antibiotic prophylaxis, amongst other strategies, to reduce infectious complications. The Cochrane Collaboration systematic review of 2011 concluded that antibacterial prophylaxis significantly reduced the incidence of all infectious outcomes studied (fever, bacteraemia, bacteriuria, urinary tract infection and hospitalization).
3 Most available data supported the use of fluoroquinolones as the most suitable prophylactic agent. Interestingly, when the duration of treatment was analysed, no significant benefit or detriment was attributed to long-course (3 day) over short (1 day/one dose) regimens.
3 Furthermore, the equivalence of single-dose ciprofloxacin to that of longer regimens has more recently been reported in a large US study. 4 The data presented here should be viewed with this in mind. It is possible that the change in the prophylaxis start time from 24 to 2 h pre-biopsy reduced the antimicrobial effect on the bowel flora, with less time for ciprofloxacin-resistant organisms to become predominant and, hence, fewer men developed urosepsis secondary to such pathogens.
5 It may also be that by timing a dose of ciprofloxacin 2 h prior to the procedure, higher and more consistent antibiotic levels in serum and prostatic tissue resulted than with the former dosing schedule. However, prophylactic regimens of ≥48 h, as administered here, may be considered unnecessarily long. Indeed, a single dose of a fluoroquinolone is currently advocated as suitable prophylaxis by the European Association of Urology (EAU). 6 Ciprofloxacin-resistant E. coli is by far the predominant pathogen in post-TRUSgpb sepsis.
7 This is not surprising, given that ciprofloxacin is the main prophylactic agent used and a significant proportion of patients have received ciprofloxacin to treat urinary infections associated with their prostatic problems. Recent studies have shown that 10% -20% of men undergoing TRUSgpb harbour quinolone-resistant organisms in their bowel prior to the administration of prophylactic antibiotics and a link between such colonization and post-TRUSgpb infection has been demonstrated. 8 The significant finding of coincident ESBL production and gentamicin resistance in up to 75% and 33% of causative organisms isolated, respectively, has also been reported. 7, 9 Total numbers in our repeated audit are still too small to usefully compare the occurrence of these two latter characteristics. However, analysis of plasmids has shown the increasing presence of multiple genes encoding ESBL enzymes and other mechanisms of resistance to important antibiotics, including gentamicin. 10 In 2009, we hypothesized that rectal screening for fluoroquinolone-resistant and ESBL-producing bacteria shortly before TRUSgpb, with antibiotic prophylaxis tailored to the results, may be more effective at reducing post-biopsy urosepsis than blanket regimen changes. 2 Although financial constraints have so far prevented such screening procedures being introduced in our
